Literature DB >> 26858889

Integration-Free Human Induced Pluripotent Stem Cells From Type 1 Diabetes Patient Skin Fibroblasts Show Increased Abundance of Pancreas-Specific microRNAs.

Jun Liu1, Mugdha V Joglekar2, Huseyin Sumer1, Anandwardhan A Hardikar2, Halena Teede3, Paul J Verma4.   

Abstract

Type 1 diabetes (T1D) is a disease that is typically associated with multigenetic changes as well as environmental triggers. Disease-specific induced pluripotent stem cells (iPSCs) are preferable cell sources to study T1D, as they are derived from patient cells and therefore capture the disease genotype in a stem cell line. The purpose of this study was to generate integration-free iPSCs from adult skin fibroblasts with T1D. iPSCs were generated by transfection of synthetic mRNAs encoding transcription factors OCT4, SOX2, KLF4, c-MYC, and LIN28. Phase-contrast microscopy, immunocytochemistry, karyotyping, bisulfite genomic sequencing, reverse transcription-polymerase chain reaction, and teratoma formation assay were used to determine reprogramming efficiency, pluripotency, and differentiation potential. Following 18 consecutive days of synthetic mRNA transfections, the T1D patient skin fibroblasts underwent morphological changes, and the aggregated clumps exhibited a human embryonic stem cell (ESC)-like morphology with a high nucleus/cytoplasm ratio. Highly efficient generation of iPSCs was achieved using the mRNA reprogramming approach. The disease-specific iPSCs expressed pluripotency markers, maintained a normal karyotype, and formed teratomas containing tissues representative of the three germ layers when injected into immune-deficient mice. Of interest, the iPSCs showed upregulations of pancreas-specific microRNAs, compared with parental fibroblasts. These data indicate that T1D patient skin fibroblasts can be reprogrammed to pluripotency using a synthetic mRNA approach. These cells can serve as a useful tool for the identification of genes that are involved in autoimmune reactions as well as generating patient-matched β-cells for cell-based therapy.

Entities:  

Keywords:  Induced pluripotent stem cells (iPSCs); Pluripotency reprogramming; Type 1 diabetes (T1D); microRNA

Year:  2014        PMID: 26858889      PMCID: PMC4733842          DOI: 10.3727/215517914X681785

Source DB:  PubMed          Journal:  Cell Med        ISSN: 2155-1790


  29 in total

1.  Late passage human fibroblasts induced to pluripotency are capable of directed neuronal differentiation.

Authors:  Jun Liu; Huseyin Sumer; Jessie Leung; Kyle Upton; Mirella Dottori; Alice Pébay; Paul J Verma
Journal:  Cell Transplant       Date:  2010-08-17       Impact factor: 4.064

2.  Epigenetic reprogramming of OCT4 and NANOG regulatory regions by embryonal carcinoma cell extract.

Authors:  Christel T Freberg; John Arne Dahl; Sanna Timoskainen; Philippe Collas
Journal:  Mol Biol Cell       Date:  2007-02-21       Impact factor: 4.138

Review 3.  Guidelines and techniques for the generation of induced pluripotent stem cells.

Authors:  Nimet Maherali; Konrad Hochedlinger
Journal:  Cell Stem Cell       Date:  2008-12-04       Impact factor: 24.633

4.  Reprogramming of mouse and human cells to pluripotency using mature microRNAs.

Authors:  Norikatsu Miyoshi; Hideshi Ishii; Hiroaki Nagano; Naotsugu Haraguchi; Dyah Laksmi Dewi; Yoshihiro Kano; Shinpei Nishikawa; Masahiro Tanemura; Koshi Mimori; Fumiaki Tanaka; Toshiyuki Saito; Junichi Nishimura; Ichiro Takemasa; Tsunekazu Mizushima; Masataka Ikeda; Hirofumi Yamamoto; Mitsugu Sekimoto; Yuichiro Doki; Masaki Mori
Journal:  Cell Stem Cell       Date:  2011-06-03       Impact factor: 24.633

5.  Cell-surface markers for the isolation of pancreatic cell types derived from human embryonic stem cells.

Authors:  Olivia G Kelly; Man Yin Chan; Laura A Martinson; Kuniko Kadoya; Traci M Ostertag; Kelly G Ross; Mike Richardson; Melissa K Carpenter; Kevin A D'Amour; Evert Kroon; Mark Moorman; Emmanuel E Baetge; Anne G Bang
Journal:  Nat Biotechnol       Date:  2011-07-31       Impact factor: 54.908

Review 6.  New pancreas from old: microregulators of pancreas regeneration.

Authors:  Mugdha V Joglekar; Vishal S Parekh; Anandwardhan A Hardikar
Journal:  Trends Endocrinol Metab       Date:  2007-12       Impact factor: 12.015

7.  Generation of pluripotent stem cells from patients with type 1 diabetes.

Authors:  René Maehr; Shuibing Chen; Melinda Snitow; Thomas Ludwig; Lisa Yagasaki; Robin Goland; Rudolph L Leibel; Douglas A Melton
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-31       Impact factor: 11.205

Review 8.  Translational mini-review series on type 1 diabetes: Immune-based therapeutic approaches for type 1 diabetes.

Authors:  T Staeva-Vieira; M Peakman; M von Herrath
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

9.  Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA.

Authors:  Luigi Warren; Philip D Manos; Tim Ahfeldt; Yuin-Han Loh; Hu Li; Frank Lau; Wataru Ebina; Pankaj K Mandal; Zachary D Smith; Alexander Meissner; George Q Daley; Andrew S Brack; James J Collins; Chad Cowan; Thorsten M Schlaeger; Derrick J Rossi
Journal:  Cell Stem Cell       Date:  2010-09-30       Impact factor: 24.633

10.  Generation of stable pluripotent stem cells from NOD mouse tail-tip fibroblasts.

Authors:  Jun Liu; Michelle P Ashton; Huseyin Sumer; Moira K O'Bryan; Thomas C Brodnicki; Paul J Verma
Journal:  Diabetes       Date:  2011-04-04       Impact factor: 9.461

View more
  5 in total

Review 1.  MiRNAs in β-Cell Development, Identity, and Disease.

Authors:  Aida Martinez-Sanchez; Guy A Rutter; Mathieu Latreille
Journal:  Front Genet       Date:  2017-01-11       Impact factor: 4.599

Review 2.  Endoplasmic reticulum stress and eIF2α phosphorylation: The Achilles heel of pancreatic β cells.

Authors:  Miriam Cnop; Sanna Toivonen; Mariana Igoillo-Esteve; Paraskevi Salpea
Journal:  Mol Metab       Date:  2017-07-12       Impact factor: 7.422

Review 3.  iPSC technology-based regenerative therapy for diabetes.

Authors:  Yasushi Kondo; Taro Toyoda; Nobuya Inagaki; Kenji Osafune
Journal:  J Diabetes Investig       Date:  2017-07-29       Impact factor: 4.232

Review 4.  Chemically modified mRNA beyond COVID-19: Potential preventive and therapeutic applications for targeting chronic diseases.

Authors:  Dana Elkhalifa; Menatallah Rayan; Ahmed T Negmeldin; Abdelbary Elhissi; Ashraf Khalil
Journal:  Biomed Pharmacother       Date:  2021-10-28       Impact factor: 6.529

Review 5.  Advances of Stem Cell Therapeutics in Cutaneous Wound Healing and Regeneration.

Authors:  Suman Kanji; Hiranmoy Das
Journal:  Mediators Inflamm       Date:  2017-10-29       Impact factor: 4.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.